Varicella zoster virus (VZV)-specific immunity and subclinical VZV reactivation in patients with autoimmune diseases
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The risk of herpes zoster (HZ) is increased in patients with autoimmune diseases (AID), probably due to immunosuppressive therapy. Methods: This prospective cross-sectional study investigated varicella zoster virus (VZV)-specific immunity in relation to subclinical VZV reactivation in 48 AID patients and 48 healthy controls (HCs). We assessed humoral immunity (serum VZV immunoglobulin g [IgG], IgA, and IgM) and cell-mediated immunity (interferon-γ [IFNγ]-releasing assay) to VZV as well as salivary VZV DNA status. Subclinical VZV reactivation was confirmed by detecting VZV DNA in saliva or VZV IgM in serum in the absence of typical HZ symptoms. Results: Median IgA levels were higher in the AID group than in the HC group, while VZV IgG and IgM levels were comparable between the groups. AID patients showed fewer IFNγ spot-forming cells (SFCs) upon VZV stimulation than HCs (58.2 vs. 122.0 SFCs/106 peripheral blood mononuclear cells [PBMCs], p < 0.0001). Subclinical VZV reactivation was more frequent in AID patients than in HCs (12.5% vs. 0%, p = 0.01). AID patients with VZV reactivation received prednisolone more frequently and at a higher dose than AID patients without reactivation. VZV-specific IFNγ SFCs were significantly lower in patients with VZV reactivation among AID patients (26.3 vs. 62.6 SFCs/106 PBMCs, p < 0.0001). Conclusions: Results suggest that poor cellular response against VZV might cause clinical and subclinical reactivation of VZV in AID patients.
Abstract
Background/Aims: The risk of herpes zoster (HZ) is increased in patients with autoimmune diseases (AID), probably due to immunosuppressive therapy. Methods: This prospective cross-sectional study investigated varicella zoster virus (VZV)-specific immunity in relation to subclinical VZV reactivation in 48 AID patients and 48 healthy controls (HCs). We assessed humoral immunity (serum VZV immunoglobulin g [IgG], IgA, and IgM) and cell-mediated immunity (interferon-γ [IFNγ]-releasing assay) to VZV as well as salivary VZV DNA status. Subclinical VZV reactivation was confirmed by detecting VZV DNA in saliva or VZV IgM in serum in the absence of typical HZ symptoms. Results: Median IgA levels were higher in the AID group than in the HC group, while VZV IgG and IgM levels were comparable between the groups. AID patients showed fewer IFNγ spot-forming cells (SFCs) upon VZV stimulation than HCs (58.2 vs. 122.0 SFCs/106 peripheral blood mononuclear cells [PBMCs], p < 0.0001). Subclinical VZV reactivation was more frequent in AID patients than in HCs (12.5% vs. 0%, p = 0.01). AID patients with VZV reactivation received prednisolone more frequently and at a higher dose than AID patients without reactivation. VZV-specific IFNγ SFCs were significantly lower in patients with VZV reactivation among AID patients (26.3 vs. 62.6 SFCs/106 PBMCs, p < 0.0001). Conclusions: Results suggest that poor cellular response against VZV might cause clinical and subclinical reactivation of VZV in AID patients.
참고문헌 (32)
- Arvin A, "Aging, immunity, and the varicella-zoster virus", N Engl J Med, 352, pp.2266~2267 (2005)
- Yun H, "Risk of herpes zoster in autoimmune and inflammatory diseases : implications for vaccination", Arthritis Rheumatol, 68, pp.2328~2337 (2016)
- Chakravarty EF, "Increased incidence of herpes zoster among patients with systemic lupus erythematosus", Lupus, 22, pp.238~244 (2013)
- Bond D, "A literature review regarding the management of varicella-zoster virus", Musculoskeletal Care, 8, pp.118~122 (2010)
- Chen HH, "Risk of herpes zoster in patients with systemic lupus erythematosus : a three-year follow-up study using a nationwide population-based cohort", Clinics (Sao Paulo), 66, pp.1177~1182 (2011)
- Veetil BM, "Incidence and time trends of herpes zoster in rheumatoid arthritis : a population-based cohort study", Arthritis Care Res (Hoboken), 65, pp.854~861 (2013)
- Aletaha D, "2010 Rheumatoid arthritis classification criteria : an American College of Rheumatology", European League Against Rheumatism collaborative initiative, 2010, pp.62, 2569~2581
- Liao TL, "significant associations of neurological complications of herpes zoster with stroke in rheumatoid arthritis patients", J Am Heart Assoc, 6, pp.e006304~ (2017)
- Calabrese LH, "Herpes zoster and the risk of stroke in patients with autoimmune diseases", Arthritis Rheumatol, 69, pp.439~446 (2017)
- Furer V, "2019 Update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases", Ann Rheum Dis, 79, pp.39~52 (2020)
- Singh JA, "2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis", Arthritis Care Res (Hoboken), 64, pp.625~639 (2012)
- Schub D, "VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs", Arthritis Res Ther, 20, pp.252~ (2018)
- Krasselt M, "Humoral immunity to varicella zoster virus is altered in patients with rheumatoid arthritis", Clin Rheumatol, 38, pp.2493~2500 (2019)
- Almanzar G, "Tofacitinib modulates the VZV-specific CD4+T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis", Rheumatology (Oxford), 58, pp.2051~2060 (2019)
- Park HB, "Association of reduced CD4 T cell responses specific to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus erythematosus", J Rheumatol, 31, pp.2151~2155 (2004)
- Rondaan C, "Longitudinal analysis of varicella-zoster virus-specific antibodies in systemic lupus erythematosus : no association with subclinical viral reactivations or lupus disease activity", Lupus, 27, pp.1271~1278 (2018)
- Prevoo ML, "Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis", Arthritis Rheum, 38, pp.44~48 (1995)
- Rondaan C, "Altered cellular and humoral immunity to varicella-zoster virus in patients with autoimmune diseases", Arthritis Rheumatol, 66, pp.3122~3128 (2014)
- Park SY, "Relationships of varicella zoster virus(VZV)-specific cell-mediated immunity and persistence of VZV DNA in saliva and the development of postherpetic neuralgia in patients with herpes zoster", J Med Virol, 91, pp.1995~2000 (2019)
- Park SY, "Diagnostic usefulness of varicella-zoster virus real-time polymerase chain reaction analysis of DNA in saliva and plasma specimens from patients with herpes zoster", J Infect Dis, 217, pp.51~57 (2017)
- Laing KJ, "Immunobiology of varicella-zoster virus infection", J Infect Dis, 218(Suppl 2), pp.S68~S74 (2018)
- Schub D, "Altered phenotype and functionality of varicella zoster virus-specific cellular immunity in individuals with active infection", J Infect Dis, 211, pp.600~612 (2015)
- Neurath MF, "Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis(CIA) : a mechanism for methotrexate-mediated immunosuppression", Clin Exp Immunol, 115, pp.42~55 (1999)
- Mehta SK, "Varicella-zoster virus in the saliva of patients with herpes zoster", J Infect Dis, 197, pp.654~657 (2008)
- Mehta SK, "Stress-induced subclinical reactivation of varicella zoster virus in astronauts", J Med Virol, 72, pp.174~179 (2004)
- Rooney BV, "Herpes virus reactivation in astronauts during spaceflight and its application on Earth", Front Microbiol, 10, pp.16~ (2019)
- Uchakin PN, "Fatigue in medical residents leads to reactivation of herpes virus latency", Interdiscip Perspect Infect Dis, 2011, pp.571340~ (2011)
- Malavige GN, "IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies", Br J Cancer, 102, pp.727~730 (2010)
- Harrison KS, "Antagonizing the glucocorticoid receptor impairs explant-induced reactivation in mice latently infected with herpes simplex virus 1", J Virol, 93, pp.e00418~e00419 (2019)
- Warren-Gash C, "Viral load and antibody boosting following herpes zoster diagnosis", J Clin Virol, 103, pp.12~15 (2018)
- Woof JM, "The function of immunoglobulin A in immunity", J Pathol, 208, pp.270~282 (2006)
- Tovi F, "The significance of specific IgA antibodies in the serum in the early diagnosis of zoster", J Infect Dis, 152, pp.230~ (1985)